Search results
Results from the WOW.Com Content Network
Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [22] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [22] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. [22] Symptoms generally resolve after a short period of time. [22]
Review the prescribing information for any weight loss pill you are considering, and be sure to tell your healthcare provider about any health conditions you have as well as any medications you ...
The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health ...
Top Prescription Weight Loss Pills. Anti-obesity medications (AOMs) date back to the 1940s — well before modern regulations from the FDA (U.S. Food and Drug Administration) (FDA) were in place ...
For prescription medications, the insert is technical, providing information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user —the person who will take the ...
For premium support please call: 800-290-4726 more ways to reach us
Weight gain: 5 times more likely to have considerable weight gain, around 40% with chlorpromazine gaining weight: RR 4.9 CI 2.3 to 10.4: Very low (estimate of effect uncertain) Sedation: 3 times more likely to cause sedation, around 30% with chlorpromazine: RR 2.8 CI 2.3 to 3.5 Acute movement disorder
As of November 17, 2004, the FDA has required a boxed warning on the Depo-Provera contraceptive injection, due to the risk of significant loss of bone density with long-term use. [ 8 ] In April 2005, FDA advisors requested that Pfizer place a boxed warning on their non-steroidal anti-inflammatory drug Celebrex ( celecoxib ) for cardiovascular ...